AAV-RPE65 vector

AAV-RPE65 gene therapy · Beacon Therapeutics

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for AAV-RPE65 vector, covering 2016-04-08 to 2016-04-08. Get the full timeline:

Most recent: Clinical Trial Update: Phase 1/2 Safety and Efficacy Study of AAV-RPE65 Vector to Treat Leber Congenital Amaurosis [Phase 1, Phase 2]